Skip to main content
Evidence Snapshot

B-lymphocyte antigen CD19

CHEMBL3390821 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:55:53Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3390821
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats B-lymphocyte antigen CD19 as ChEMBL target CHEMBL3390821, mapped to UniProt P15391. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
B-lymphocyte antigen CD19
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3390821
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P15391
B-lymphocyte antigen CD19
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why B-lymphocyte antigen CD19 matters

As of 2026-09-13

B-lymphocyte antigen CD19 is reviewed as B-lymphocyte antigen CD19 (UniProt P15391); B-lymphocyte antigen CD19 shows approved-linked disease relevance led by acute lymphoblastic leukemia. 5 more disease programs remain visible in the same review block.; 9 linked drugs keep this evidence frame grounded..

Disease context
acute lymphoblastic leukemia

B-lymphocyte antigen CD19 shows approved-linked disease relevance led by acute lymphoblastic leukemia. 5 more disease programs remain visible in the same review block. 9 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include BLINATUMOMAB, BREXUCABTAGENE AUTOLEUCEL, COLTUXIMAB RAVTANSINE.

Start review with acute lymphoblastic leukemia because it currently carries approved-linked support. Linked drugs include BLINATUMOMAB, BREXUCABTAGENE AUTOLEUCEL, COLTUXIMAB RAVTANSINE, DENINTUZUMAB MAFODOTIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 9 linked drugs
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why B-lymphocyte antigen CD19 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P15391, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why acute lymphoblastic leukemia is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

0
Total Compounds
0
Total Assays
0
Approved Drugs
-
Activity Types

pChEMBL Activity Distribution

← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:55:53Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3390821